Foot and ankle injuries
Conditions
Interventions
Group LB (liposomal bupivacaine combined with bupivacaine):Popliteal sciatic nerve block: 10 ml of 0.25% bupivacaine + 10 ml of 1.33% liposomal bupivacaine totaling 20 ml
Saphenous nerve block: 5 ml of 0.25% bupivacaine + 5 ml of 1.33% liposomal bupivacaine, totaling 10 ml
Group B (bupivacaine):Popliteal sciatic nerve block: 20 ml of 0.25% standard bupivacaine in a total of 20 ml
Saphenous nerve block: 10 ml of 0.25% standard bupivacaine in a total volume of 10 ml
Group R (ropivacaine):Popliteal sciatic nerve block: 20 ml of 0.25% ropivacaine hydrochloride in a total of 20 ml
Saphenous nerve block: 10 ml of 0.25% ropivacaine hydrochloride in a total volume of 10 ml
Sponsors
Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming City, Yunnan Province"
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 65 years. 2.American Society of Anesthesiologists (ASA) physical status classification = Grade 1–3. 3.Patients with primary surgical indications related to the foot and ankle who are scheduled for elective surgical treatment.
Exclusion criteria
Exclusion criteria: 1.Patients with severe cardiac, pulmonary, cerebral, or hepatic/renal dysfunction, or with serious endocrine disorders. 2.Patients with preoperative coagulation disorders or those on long-term anticoagulant therapy. 3.Patients who are allergic or intolerant to the study drug, or have contraindications to its use. 4.Patients with a history of chronic pain unrelated to foot and ankle surgery (e.g., arthritis, fibromyalgia). 5.Patients with sensory dysfunction of the foot/ankle. 6.Patients with a history of alcohol or drug abuse within the past 2 years. 7.Patients who have used opioids long-term (average daily oral dose = 30 mg morphine equivalent [MME]) within 30 days prior to the start of the study. 8.Patients with psychiatric disorders, communication difficulties, or those who refuse to cooperate. 9.Patients with allergies to ultrasound coupling agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient's overall quality of recovery within 48 postoperative hours (as reflected by QoR-15 scores preoperatively and at 48h postoperatively); | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's visual analog (VAS) pain score in the 24h postoperative period;Patient Sensory Block Success Rate, and Sensory Block, Motor Block Score;Patient opioid consumption in the 24h postoperative period;Incidence of Adverse Events Associated with Neurologic Blockade;Total length of stay;Lower limb skin temperature changes before and after block; | — |
Countries
China
Contacts
Public ContactYu Fang
The First Affiliated Hospital of Kunming Medical University
Outcome results
None listed